Skip to content

Observation on the Clinical Efficacy of Henggu Bone Trauma Healing Agent in the Treatment of Lumbar Disc Herniation Combined with Osteoporosis

Observation on the Clinical Efficacy of Henggu Bone Trauma Healing Agent in the Treatment of Lumbar Disc Herniation Combined with Osteoporosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001173
Enrollment
Unknown
Registered
2026-05-07
Start date
2023-03-30
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar Disc Herniation and Osteoporosis

Interventions

Control Group:Diclofenac Sodium Enteric-coated Sustained-release Capsules, Methylcobalamin Tablets, Calcium Carbonate D3 Tablets (II)
Observation group:Combined use of Henggu bone injury healing agent on the basis of the control group.

Sponsors

Hunan Provincial Research Institute of Traditional Chinese Medicine Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Meets the diagnostic criteria for diseases related to LDH and OP as well as Chinese medicine syndrome; (2) Patients seeking treatment for LDH-related illness (new onset or recurrence); (3) Age between 55 and 75 years; (4) No use of NSAIDs or anti-osteoporosis medications within the past month; (5) Voluntarily participates and signs the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with severe underlying diseases such as heart, brain, liver, kidney, or tumor conditions; (2) Patients with diseases affecting bone metabolism, such as thyroid diseases, diabetes, or rheumatoid arthritis; (3) Patients undergoing surgery for lumbar disc herniation or osteoporotic fractures; (4) Patients allergic to the study medication; (5) Patients with poor compliance; (6) Patients who withdraw from the study due to severe adverse reactions or other reasons.

Design outcomes

Primary

MeasureTime frame
Serum bone turnover markers:(osteocalcin, OC) (procollagen type 1 C-peptide, P1NP) (ß cross-linked C-telopeptide of type 1 collagen, ß-CTX);

Secondary

MeasureTime frame
numeric rating scales, NRS;Roland Morris Questionnaire,RMQ;Functional Status in Activities of Daily Living;Serum inflammatory factor expression levels:(tumor necrosis factor-a, TNF-a) (interleukin, IL-17) (prostaglandin E2, PGE2) ;Safety observation: Blood routine examination and liver and kidney function indicators were tested before and after treatment.;

Countries

China

Contacts

Public ContactKuang Jianjun

Hunan Province Institute of Traditional Chinese Medicine

13786165656@163.com13786165656

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 11, 2026